Engineering monoclonal antibodies for COVID-19 prophylaxis

The therapeutic and prophylactic uses of monoclonal antibodies (mABs) against SARS-CoV-2 are limited by their short half-life and need for intravenous delivery. In this issue, Cobb et al.(1) engineer a neutralizing mAB cocktail with extended half-life that can be delivered intramuscularly to provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Izadpanah, Amin, Rappaport, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915435/
https://www.ncbi.nlm.nih.gov/pubmed/35291730
http://dx.doi.org/10.1016/j.medj.2022.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915435/
https://www.ncbi.nlm.nih.gov/pubmed/35291730
http://dx.doi.org/10.1016/j.medj.2022.02.004

Ejemplares similares